Se você vai ao ASH, selecionamos alguns tópicos relacionados ao TMO que podem interessá-lo. Confira:

**Sexta-feira, 4/12:**

Telomere Dysfunction and Senescence in Marrow Failure Syndrome  
1:00 PM-6:00 PM Tangerine 2 (WF2), Level 2 (Orange County Convention Center)  
Rodrigo T. Calado, MD, PhD, Ribeirão Preto

**Sábado, 5/12- Série “How I Treat: Bringing Science to Clinical Dilemmas”**

Children with Histiocytic Disorders  
11:15 AM-12:15 PM Bayhill 19 (Hyatt Regency Orlando)  
Oussama Abla, MD, The Hospital for Sick Children

Double Hit Lymphoma  
11:15 AM-12:15 PM Bayhill 21 (Hyatt Regency Orlando)  
Kristie A. Blum, MD, The Ohio State University

Myelofibrosis  
11:15 AM-12:15 PM Bayhill 29 (Hyatt Regency Orlando)  
John O. Mascarenhas, MD, MS, Mount Sinai School of Medicine

Transfusion Challenges in Sickle Cell Disease  
11:15 AM-12:15 PM Bayhill 20 (Hyatt Regency Orlando)  
Cassandra Josephson, MD, Emory University

Young Patients with Chronic Lymphocytic Leukemia  
11:15 AM-12:15 PM Bayhill 18 (Hyatt Regency Orlando)
John Gribben, MD, DSc, Barts Cancer Center, The London School of Medicine

Hematopoietic Stem Cell Transplantation in Sickle Cell Disease and Thalassemia
11:15 AM-12:15 PM Bayhill 28 (Hyatt Regency Orlando)
John F. Tisdale, MD, NHLBI / NIDDK, NIH

Série “Meet the Scientist”

Pediatric Myeloid Neoplasms
11:15 AM-12:15 PM Bayhill 30 (Hyatt Regency Orlando)
Charlotte Marie Niemeyer, Prof, MD, Children's Hospital, University Medical Center

Sábado - Trabalhos orais

66 Feasibility of Azacitidine As Bridge to Allogeneic Stem Cell Transplantation in Patients with Higher-Risk MDS or Low-Blast Count AML: Results of the BMT-AZA Multicenter Prospective Study
10:45 AM W304, Level 3 (Orange County Convention Center)
Maria Teresa Voso
https://ash.confex.com/ash/2015/webprogram/Paper79705.html

99 Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft-Versus-Host Disease
12:30 PM W314, Level 3 (Orange County Convention Center)
Jennifer N Brudno NIH
https://ash.confex.com/ash/2015/webprogram/Paper81459.html
151 Related Nonmyeloablative Haploidentical (mini-haplo) Blood or Marrow Transplantation (BMT) with High-Dose Post-Transplant Cyclophosphamide (PTCy) for Acute Myeloid Leukemia (AML): Donor Age Impacts Outcome
4:00 PM W304, Level 3 (Orange County Convention Center)
Margaret M. Showel JHH
https://ash.confex.com/ash/2015/webprogram/Paper83765.html

152 Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation
4:15 PM W304, Level 3 (Orange County Convention Center)
Sameh Gaballa the University of Texas MD Anderson Cancer Center
https://ash.confex.com/ash/2015/webprogram/Paper82529.html

Sábado - Posteres: apresentação dos autores 5:30 PM-7:30 PM
Hall A, Level 2 (Orange County Convention Center)

1904 Randomized Trial of Micafungin Versus Fluconazole in Prophylaxis Against Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients
Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities
Silvia Park – Korea
https://ash.confex.com/ash/2015/webprogram/Paper81863.html

1916 Intensification of the Regimen Fludarabine Melphalan with the Addition of 400 Cgy of Total Body Irradiation in Allogeneic Stem Cell Transplantation. It Is Feasible, Has a Good Anti-Leukemic Effect and a Low Toxicity
Amado J Karduss-Urueta – Colombia
https://ash.confex.com/ash/2015/webprogram/Paper81541.html
Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities
Rocco Pastano – Milão, Italia

https://ash.confex.com/ash/2015/webprogram/Paper87109.html

1933 Histologic Confirmation for Patients Presenting with Gastrointestinal Graft Versus Host Disease: How to Interpret Histologic Grade 1 (Does It Matter)?
Jin S. Im - The University of Texas MD Anderson Cancer Center, Houston, TX

https://ash.confex.com/ash/2015/webprogram/Paper81945.html

1960 T Cell Replete HLA- Haploidentical Donor Transplantation (HIDT) with Post-Transplant Cyclophosphamide (pTcy) Is an Effective Salvage for Patients Relapsing after a Matched Sibling or a Matched Unrelated Donor Transplantation
Melhem Solh - The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA

https://ash.confex.com/ash/2015/webprogram/Paper82092.html

1962 Pilot Study of Radiation-Targeted Donor Lymphocyte Infusion for Cancer Progression
Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence
Nancy M. Hardy - University of Maryland School of Medicine, Baltimore, MD; NIH

https://ash.confex.com/ash/2015/webprogram/Paper80893.html

1980 Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM
Yago Nieto - University of Texas MD Anderson Cancer Center, Houston, TX

https://ash.confex.com/ash/2015/webprogram/Paper83730.html
1985 Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity
Perrine Guillaume-Jugnot BMT-ADWP
https://ash.confex.com/ash/2015/webprogram/Paper79536.html

1986 Outcomes of Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Salvage Chemotherapy and Intention to Transplant in the Rituximab Era
Santosha A. Vardhana - Memorial Sloan Kettering Cancer Center, New York, NY
https://ash.confex.com/ash/2015/webprogram/Paper79986.html

1990 Non-Cryopreserved Hematopoietic Stem Cell Transplantation in Multiple Myeloma. a Single Center Experience in Oran (ALGERIA)
Amine MA Bekadja - Algeria
https://ash.confex.com/ash/2015/webprogram/Paper82651.html

2002 Nonmyeloablative (NMA), HLA-Mismatched Unrelated Donor (mMUD) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Has Outcomes Similar to Matched BMT
Yvette L. Kasamon - Johns Hopkins University, Baltimore, MD
https://ash.confex.com/ash/2015/webprogram/Paper77712.html

2007 The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma
Natasha Kekre - Dana Farber Cancer Institute e Spanish Group of Transplantation (GETH)
https://ash.confex.com/ash/2015/webprogram/Paper79506.html

2010 Disease Risk Index Is the Major Predictor of Outcome Following Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT) and Post-Transplant Cyclophosphamide (PT/Cy)
Scott R. Solomon - Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA
https://ash.confex.com/ash/2015/webprogram/Paper79607.html
2031 Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Refractory Severe Aplastic Anemia (SAA)
Amy E. DeZern - The Johns Hopkins School of Medicine, Baltimore, MD
https://ash.confex.com/ash/2015/webprogram/Paper78144.html

Domingo, 6/12

Série “Meet the Scientist”

Aplastic Anemia
11:15 AM-12:15 PM Bayhill 29 (Hyatt Regency Orlando)
Cynthia E. Dunbar, MD, National Institutes of Health

Educacional – “Special-Interest Sessions”

The Epic Story of Blood
4:30 PM-5:45 PM Chapin Theater (W320), Level 3 (Orange County Convention Center)
Bob Löwenberg, MD, PhD, Editor-in-Chief, Blood, Erasmus University Medical Center

The Health Volunteers Overseas Experience: Sharing Your Hematology Expertise Globally
7:00 PM-8:00 PM W305 (Orange County Convention Center)

Domingo – Trabalhos orais

193 Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age
7:30 AM W304, Level 3 (Orange County Convention Center)
Ehab Atallah – CIBMTR

194 Survival after T-Cell Replete Haploidentical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor (MUD) Transplant for Lymphoid Malignancies
7:45 AM W304, Level 3 (Orange County Convention Center)

Alberto Mussetti – CIBMTR
https://ash.confex.com/ash/2015/webprogram/Paper79896.html

196 Comparison of Matched-Sibling Donors Versus Unrelated Donors in Allogeneic Stem Cell Transplantation (allo-SCT) for Primary Refractory Acute Myeloid Leukemia (PRF AML): A Report of 1041 Patients from the Acute Leukemia Working Party of the EBMT
8:15 AM - W304, Level 3 (Orange County Convention Center)

Eolia Brissot
https://ash.confex.com/ash/2015/webprogram/Paper78942.html

197 Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Provides Durable Progression-Free Survival (PFS) in a Subset of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous (auto-) HCT
8:30 AM W304, Level 3 (Orange County Convention Center)

Timothy S. Fenske - CIBMTR
https://ash.confex.com/ash/2015/webprogram/Paper77855.html

198 Allogeneic Stem Cell Transplantation for Relapsed / Refractory (R/R) Follicular Lymphoma (FL). a Joint Study Between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR)
8:45 AM W304, Level 3 (Orange County Convention Center)

Anna Sureda
https://ash.confex.com/ash/2015/webprogram/Paper85621.html

265 The Impact of Pre-Transplant Depression on Outcomes of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation
12:00 PM W340, Level 3 (Orange County Convention Center)

Areej El-Jawahri
https://ash.confex.com/ash/2015/webprogram/Paper81129.html
Domingo – Posteres: apresentação dos autores 6:00 PM-8:00 PM

Hall A, Level 2 (Orange County Convention Center)

3104 Detection of Multiple Double-Stranded DNA Viruses after Cord Blood Transplantation Is Frequent and Persistent
Joshua A Hill - Fred Hutchinson Cancer Research Center, Seattle, WA
https://ash.confex.com/ash/2015/webprogram/Paper80737.html

3105 Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with High-Risk AML in Complete Remission: A Survey from the ALWP of the EBMT
Florent Malard
https://ash.confex.com/ash/2015/webprogram/Paper78720.html

3106 T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy
Ramzi Abboud - Washington University School of Medicine, Saint Louis, MO
https://ash.confex.com/ash/2015/webprogram/Paper81455.html

3107 Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Following Hematopoietic Stem Cell Transplantation or Chemotherapy--Results from the Italian Therapeutic Use Protocol
Franco Locatelli – Italian Therapeutic Use Study Group
https://ash.confex.com/ash/2015/webprogram/Paper80304.html

3116 Use of Antibiotic Lock for Salvage of Tunneled Central Venous Catheters with Catheter Colonisation and Catheter Related Blood Stream Infection in a Tertiary Care Hematopoietic Stem Cell Transplantation Unit- a Strategy Revisited
Saurabh Zanwar - India
https://ash.confex.com/ash/2015/webprogram/Paper82094.html
3117 Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306
Reed Friend - University of North Carolina School of Medicine, Chapel Hill, NC
https://ash.confex.com/ash/2015/webprogram/Paper84092.html

3118 Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for High Risk Acute Pediatric Leukemia. Promising Results Using a Protocol with Peripheral Blood and a Medium Intensity Conditioning
Amado J Karduss-Urueta - Colombia
https://ash.confex.com/ash/2015/webprogram/Paper82323.html

3121 Defibrotide for the Treatment of Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with/without Multi-Organ Dysfunction Following Chemotherapy: Results from an Ongoing Expanded Access Program
Nancy A. Kernan – Multi-institucional EUA e Jazz Pharmaceuticals, Palo Alto, CA
https://ash.confex.com/ash/2015/webprogram/Paper80576.html

3151 Development and Preliminary Usability and Accuracy Testing of the EBMT Gvhd App to Support Graft Versus Host Disease Diagnosis and Scoring According to NIH Criteria, By the EBMT Complications and Quality of Life Working Party
Schoemans Helene
https://ash.confex.com/ash/2015/webprogram/Paper86372.html

3154 Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report
Andrew C. Harris
https://ash.confex.com/ash/2015/webprogram/Paper79609.html

3169 Impact of Routine Surveillance Imaging on Outcomes in Patients with Classical Hodgkin Lymphoma (cHL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)
Jonathan Kapke - CIBMTR
https://ash.confex.com/ash/2015/webprogram/Paper84095.html
3172 Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse
John Sweetenham – Multi-institucional, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals Limited, Cambridge, MA e Seattle Genetics, Inc., Bothell, WA
https://ash.confex.com/ash/2015/webprogram/Paper79005.html

3185 Targeted Oral Busulfan (BU)/Cyclophosphamide (CY)/VP-16 and Autologous Stem Cell Transplant (ASCT) for Hodgkin's (HL) and Non-Hodgkin's Lymphoma (NHL) Results in Excellent 5-Year Survival and Low Treatment-Related Mortality: Ten-Year Single Center Experience of 246 Consecutively Treated Patients
Scott R. Solomon - Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA
https://ash.confex.com/ash/2015/webprogram/Paper79610.html

3195 Consolidative Radiation Therapy Following Autologous Transplantation in Relapsed or Refractory Hodgkin Lymphoma
Shekeab Jauhari - University of Pennsylvania, Philadelphia, PA
https://ash.confex.com/ash/2015/webprogram/Paper78281.html

3202 Allogeneic Hematopoietic Cell Transplantation for Adult Patients with ALL: Current Results and Prognostic Factors. an Analysis from Acute Leukemia Working Party of the EBMT
Sebastian Giebel
https://ash.confex.com/ash/2015/webprogram/Paper82086.html

3225 Outcomes of Haploidentical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience
Reshma Ramlal - University of Texas MD Anderson Cancer Center, Houston, TX
https://ash.confex.com/ash/2015/webprogram/Paper83731.html

3262 Inpatient Utilization Among Children and Adolescents with Sickle Cell Disease: Analysis of a Large Populated-Based Retrospective Cohort
Rodney Theodore - Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
https://ash.confex.com/ash/2015/webprogram/Paper86574.html
Segunda, 7/12

**Education Spotlight Non-Malignant**

Infections and the Blood Supply  
10:30 AM-12:00 PM W312, Level 3 (Orange County Convention Center)

Addressing Severe Thrombocytopenia in the Care of Patients with Myelodysplastic Syndromes and Other Hematological Malignancies  
2:45 PM-4:15 PM W312, Level 3 (Orange County Convention Center)

**Segunda - Apresentações orais**

521 Progression-Free Survival at 24 Months (PFS24) and Complete Response at 30 Months (CR30) from Autologous Stem Cell Transplantation (ASCT) Should be Used As Surrogates for OS in Follicular Lymphoma (FL) Patients  
8:00 AM W224CDGH, Level 2 (Orange County Convention Center)

Ana Jiménez Ubieto - Hematologia, Hospital 12 de Octubre, Madrid, Spain  

522 Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation  
8:15 AM W224CDGH, Level 2 (Orange County Convention Center)

Alex F. Herrera - City of Hope Medical Center, Duarte, CA  

621 Hematopoietic Stem Cell Transplantation for Hemophagocytic Lymphohistiocitosis : A National Retrospective Analysis of Data from the Italian Association of Pediatric Hematology Oncology (AIEOP)  
11:00 AM W230, Level 2 (Orange County Convention Center)

Chiara Messina  
736 Fludarabine Busulfan Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities
3:30 PM W230, Level 2 (Orange County Convention Center)
Moussab Damlaj - Division of Hematology, Mayo Clinic, Rochester, MN
https://ash.confex.com/ash/2015/webprogram/Paper79843.html

737 Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial
3:45 PM W230, Level 2 (Orange County Convention Center)
Paul G. Richardson – Multi-institucional

864 Hematopoietic Cell Transplantation with or without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1
5:45 PM Tangerine 2 (WF2), Level 2 (Orange County Convention Center)
Andrew M. Brunner - Dana-Farber Cancer Institute, Boston, MA
https://ash.confex.com/ash/2015/webprogram/Paper82275.html

877 Cognitive, Behavior and Academic Problems in Adolescent Survivors of Childhood Acute Lymphoblastic Leukemia (ALL): A Report from the Childhood Cancer Survivor Study Health Services and Outcomes Research – Malignant Diseases
4:30 PM Chapin Theater (W320), Level 3 (Orange County Convention Center)
Lisa M Jacola - St. Jude Children's Research Hospital, Memphis, TN
https://ash.confex.com/ash/2015/webprogram/Paper79434.html
880 Cardiovascular Disease in Adolescents and Young Adults with Hematologic Malignancies
Health Services and Outcomes Research – Malignant Diseases
5:15 PM Chapin Theater (W320), Level 3 (Orange County Convention Center)

Chun Chao - Kaiser Permanente Southern California, Pasadena, CA
https://ash.confex.com/ash/2015/webprogram/Paper80821.html

926 Autologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission: Better Outcome Following Busulfan and Melphalan Compared to Busulfan and Cyclophosphamide: A Retrospective Study from the Acute Leukemia Working Party of the EBMT
6:30 PM W314, Level 3 (Orange County Convention Center)

Norbert Claude Gorin

928 Autologous Transplant, and Not ATO Alone, Remains the Preferred Therapy for Relapsed APL: A Report from the CIBMTR, EBMT and Two Specialized Centers
Clinical Autologous Transplantation: Results
7:00 PM W314, Level 3 (Orange County Convention Center)

Chezi Ganzel
https://ash.confex.com/ash/2015/webprogram/Paper80077.html

**Segunda - Posteres: apresentação dos autores 6:00 PM-8:00 PM**

Hall A, Level 2 (Orange County Convention Center)

4360 Impact of Routine Surveillance Imaging on Outcomes in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)
Narendranath Epperla – Multi-institucional - EUA
https://ash.confex.com/ash/2015/webprogram/Paper83999.html